• Profile
Close

A comparison study on efficacy, insulin sensitivity and safety of glimepiride/metformin fixed dose combination vs glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy

Diabetes Research and Clinical Practice Jul 24, 2019

Yu HM, et al. - Researchers conducted this randomized, open-label, parallel, 16-week trial to investigate the effectiveness, insulin sensitivity, and safety of administering sulfonylurea-based drugs and metformin combined with basal insulin. For this investigation, 97 type 2 diabetic patients were chosen and randomized into an insulin glargine plus fixed-dose combination glimepiride 1 mg and metformin 500 mg twice daily group (the G/M group) and an insulin glargine plus glimepiride 4 mg once daily group (the G group). A significantly larger reduction in HbA1c and 2-hour post prandial glucose was seen with the G/M group vs the G group. Both therapies are relatively safe but the G/M group was more effective in lowering blood glucose levels.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay